Gravitas Medical

CA - San FranciscoBiotechnology2 H-1B visas (FY2023)

Focus: Gravitas Medical is a San Francisco-based biotech company founded in 2023 specializing in feeding tube monitoring devices. The company operates in a nascent stage with minimal disclosed financial data and no current job openings.

Cardiovascular Neurology Metabolic Diseases Nephrology

Profile data last refreshed 7h ago · AI intelligence enriched 2d ago

Open Jobs

About Gravitas Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Gravitas Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

ATORVASTATIN CALCIUM

Type 2 diabetes mellitus; heart failure

$1K Part D

Post-LOE

Generic statin generating minimal Part D revenue, likely near or past exclusivity cliff.

Help build intelligence for Gravitas Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build core infrastructure at a newly founded company with potential to establish market leadership in an underserved medical device category
Access to work on devices across multiple high-prevalence therapeutic areas including cardiovascular, neurology, and metabolic diseases
Strong immigration sponsorship track record: 2 approved H-1B petitions with zero denials in 2023

Watch Out For

Extreme early-stage risk: founded in 2023 with no disclosed funding, revenue, or employee count; zero active job openings signals minimal hiring activity
Severe strategic mismatch: company claims feeding tube monitoring as specialty but portfolio consists entirely of post-LOE generic drugs (atorvastatin, amlodipine, bupropion, escitalopram), suggesting data inaccuracy or abandoned core mission
No pipeline catalysts: 3 total clinical programs all in pre-clinical/guidance phase with no Phase 1–3 trials, and minimal published research (0 publications on record)

Generated by Claude from Gravitas Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AMLODIPINE BESYLATE

Hypertension; blood pressure reduction

$643 Part D

Post-LOE

Post-LOE calcium channel blocker with negligible Medicare Part D spending.

BUPROPION HYDROCHLORIDE

Major depressive disorder (MDD)

Post-LOE

Generic antidepressant with no reportable Part D spending; likely low-margin commodity.

ESCITALOPRAM OXALATE

Anxiety

Post-LOE

SSRI generic with minimal market presence and no Part D revenue data.

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

Post-LOE

Combination opioid-analgesic with no indication data or revenue disclosure.

Pipeline & Clinical Trials

Nasogastric Tube

N/A

Clinical Trials (1)

NCT05517707Gravitas Feeding Tube System Placement in Neonates

N/A

Feeding tube

Healthy Adults

N/A

Gravitas FT and Gravitas FT Monitor guidance

Nasogastric Tube

N/A

Clinical Trials (1)

NCT05914064Gravitas Feeding Tube System Placement Validation in Neonates

N/A

Entarik Feeding Tube System

Nasogastric Tube

N/A

Clinical Trials (1)

NCT05884216Entarik Feeding Tube System Placement in Adult ICU

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 47 approved products, 3 clinical trials

Top TAs: Cardiovascular, Neurology, Metabolic Diseases

H-1B (2023): 2 approvals

Portfolio Health

Post-LOE47 (100%)

47 total products

Therapeutic Area Focus

5 marketed

4 marketed

3 marketed

2 marketed

2 marketed

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

ESCITALOPRAM OXALATE

escitalopram

12.1 Mechanism of Action The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). 12.2 Pharmacodynamics In vitro and in vivo studies in animals suggest that escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Escitalopram is at least 100-fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake and inhibition of 5-HT neuronal firing rate. Tolerance to a model of antidepressant effect in rats was not induced by long-term (up to 5 weeks) treatment with escitalopram. Escitalopram has no or very low affinity for serotonergic (5-HT 1-7 ) or other receptors including alpha- and beta-adrenergic, dopamine (D 1-5 ), histamine (H 1-3 ), muscarinic (M 1-5 ), and benzodiazepine receptors. Escitalopram also does not bind to, or has low affinity for, various ion channels including Na, K, Cl, and Ca channels. Antagonism of muscarinic, histaminergic, and adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular side effects of other psychotropic drugs. 12.3 Pharmacokinetics The single- and multiple-dose pharmacokinetics of escitalopram are linear and dose-proportional in a dose range of 10 to 30 mg/day. With once-daily dosing, steady state plasma concentrations are achieved within approximately one week. At steady state, the extent of accumulation of escitalopram in plasma in young healthy subjects was 2.2-2.5 times the plasma concentrations observed after a single dose. Absorption The absolute bioavailability of citalopram is about 80% relative to an intravenous dose. The tablet and the oral solution dosage forms of escitalopram oxalate are bioequivalent. Following a single oral dose (20 mg tablet or solution) of escitalopram, peak blood levels occur at about 5 hours. Absorption of escitalopram is not affected by food. Distribution The binding of escitalopram to human plasma proteins is approximately 56%. The volume of distribution of citalopram is about 12 L/kg. Data specific on escitalopram are unavailable. Elimination Biotransformation of escitalopram is mainly hepatic, with a mean terminal half-life of about 27-32 hours. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. Metabolism Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT). In humans, unchanged escitalopram is the predominant compound in plasma. At steady state, the concentration of the escitalopram metabolite S-DCT in plasma is approximately one-third that of escitalopram. The level of S-DDCT was not detectable in most subjects. In vitro studies show that escitalopram is at least 7 and 27 times more potent than S-DCT and S-DDCT, respectiv

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Gravitas Medical

About Gravitas Medical

Why Work Here

Key Products

Watch Out For

Products & Portfolio (16)

Key Products by Revenue

Other Products (14)

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship